Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials

CellCentric, backed by Pfizer and other global investors, has raised $120 million in Series C financing to advance its oral p300/CBP inhibitor, inobrodib, for multiple myeloma treatment25.

The funding will enable phase 2/3 trials of inobrodib, targeting patients with heavily pretreated or relapsed/refractory multiple myeloma15.

Inobrodib is currently being tested in combination with dexamethasone and Bristol Myers Squibb’s Imnovid (pomalidomide) in a phase 2a study5.

The new investment will support a potential accelerated approval filing with the FDA and also help initiate a phase 3 program15.

Key backers in this round include RA Capital Management, Forbion, Avego Bioscience Capital, and the American Cancer Society’s venture capital arm5.

Sources:

1. https://endpts.com/cellcentric-raises-120m-to-treat-multiple-myeloma-with-capsule/

2. https://www.businessweekly.co.uk/posts/cellcentric-raises-120m-from-global-backers-to-advance-drug-for-multiple-myeloma

5. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25